A Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6023 Combination Therapy for Unresectable Locally Advanced or Metastatic Breast Cancer

This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Start Date25 May 2026

Sponsor / Collaborator

CSPC Megalith Biopharmaceutial Co., Ltd.

NCT07441460

/ RecruitingPhase 3

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of KN026 Combined With HB1801 and Chemotherapy Versus Trastuzumab Combined With Pertuzumab and Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer

This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.

Start Date06 Mar 2026

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

NCT07332533

/ Not yet recruitingPhase 2/3

A Phase II/III Study of KN026 Combined Chemotherapy With or Without Enlonstobart as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer.

This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.

Start Date30 Dec 2025

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

100 Clinical Results associated with Anbenitamab

100 Translational Medicine associated with Anbenitamab

100 Patents (Medical) associated with Anbenitamab

Literatures (Medical) associated with Anbenitamab

01 Jun 2026·ANNALS OF ONCOLOGY

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial

Article

Author: Liu, Z ; Liu, R ; Wu, X ; Li, Z ; Qin, Y ; Chen, Y ; She, L ; Ba, Y ; Liu, B ; Hou, X ; Li, S ; Xu, J ; Xie, Y ; Zhang, R ; Ning, F ; Deng, T ; An, Y ; Huang, M ; Liu, Y ; Zhao, J ; Du, Y ; Zhang, H ; Liu, Y P ; Yang, M ; Zou, K ; Qu, Y ; Yang, H ; Liu, C

BACKGROUND:

Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS).

PATIENTS AND METHODS:

This multicenter, randomized, double-blind, phase III trial was conducted at 51 hospital sites in China. Patients with HER2-positive gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma whose previous therapy containing trastuzumab had failed were randomized (1 : 1) to receive anbenitamab 30 mg/kg or placebo every 3 weeks, in combination with chemotherapy (paclitaxel 175 mg/m² or docetaxel 75 mg/m² on day 1 of a 21-day cycle, or irinotecan 125 mg/m² on day 1 and 8 of a 21-day cycle), stratified by combined chemotherapy [taxane (paclitaxel or docetaxel) or irinotecan], HER2 expression [immunohistochemistry (IHC) 3+ or IHC 2+/FISH+], and previous lines of therapy (1 or ≥2). Primary endpoints were independent review committee-assessed PFS and OS in the intention-to-treat population. This interim analysis was planned when ∼120 PFS events were observed.

RESULTS:

A total of 188 patients were enrolled and assigned to receive anbenitamab plus chemotherapy (anbenitamab group, n = 95) or chemotherapy alone (control group, n = 93). At the prespecified interim analysis, anbenitamab plus chemotherapy significantly improved PFS [median 7.1 months, 95% confidence interval (CI) 5.5-10.3 months versus 2.7 months, 95% CI 1.5-3.0 months; hazard ratio (HR), 0.25, 95% CI 0.17-0.39, P < 0.0001] and OS (median 19.6 months, 95% CI 15.0 months to not evaluable versus 11.5 months, 95% CI 6.5-14.4 months; HR 0.29, 95% CI 0.17-0.50, P < 0.0001) compared with chemotherapy alone. Grade 3 or higher treatment-related adverse events occurred in 56 (60%) of 94 patients who received anbenitamab plus chemotherapy and 42 (45%) of 93 patients who received chemotherapy alone, with neutropenia (30% versus 22%) and leukopenia (21% versus 25%) being most common. Treatment-related deaths were reported in 0 and 5 patients in the anbenitamab and control groups, respectively.

CONCLUSIONS:

Compared with chemotherapy alone, anbenitamab plus chemotherapy demonstrated clinically meaningful superior PFS and OS in patients with HER2-positive GC/GEJ adenocarcinoma whose previous therapy containing trastuzumab had failed. These findings warrant confirmation in the final analysis.

01 Apr 2026·Nature Reviews Clinical Oncology

Anbenitamab is a new second-line option in G/GEJ adenocarcinoma

Article

Author: Romero, Diana

20 Feb 2026·BRITISH JOURNAL OF CANCER

Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer

Article

Author: Zhang, Qingyuan ; Zhao, Wenhui ; Tang, Dabei ; Luo, Haitao ; Song, Ying ; Wang, Jingxuan ; Deng, Yuwei ; Ma, Jianli ; Tang, Xiaowen ; Liu, Xuhui ; Li, Liru ; Sun, Shengnan

BACKGROUND:

KN026 is a novel bispecific HER2-targeting antibody for HER2-positive recurrent or metastatic breast cancer that showed prolonged median PFS and lessened distinction of PFS regarding the HR subgroup in our phase II clinical trial, compared with PUFFIN study of first-line trastuzumab combined with pertuzumab therapy. A more detailed discovery of its peculiarity is needed for optimal application of KN026 treatment.

METHODS:

We performed whole-transcriptome sequencing of digital spatial profiling (DSP) on 8 pre/post-treatment tumor samples. Mechanistic explorations were conducted by plasmid transfection, co-culture, CCK8 proliferation assay and flow cytometry.

RESULTS:

Compared to the tumor regions with non-objective response (OR), those with OR had high expression of CALML5, TFAP2B, and ERBB2, and relatively low expression of ESR1 in tumor cells at baseline. The expression of ESR1 had a tentative association with PI3K/AKT and NOTCH signaling pathways which were downstream or interactive pathways of HER2 target and also acted as interactive pathways of ER-mediated signaling. The co-expression of ERBB2 and CDK12 emerged as a distinctive signature of OR. KN026 treatment also reshaped intratumoral activated T- and B-cell subtypes in hot-tumor regions, regardless of myeloid-derived cells.

CONCLUSIONS:

Both HER2 and ESR1 are determinant of KN026 efficacy in advanced HER2-positive breast cancer, implying the potential of KN026 combined with endocrine therapy in HER2- and ER-positive breast cancer.

News (Medical) associated with Anbenitamab

03 Aug 2026

·www.biospace.com

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab. Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive license to research, develop, manufacture and commercialize JSKN016 in territories outside the Chinese Mainland, Hong Kong, Macau and Taiwan, with Pathos bearing all related development and commercialization costs and expenses under the agreement. Alphamab retains its full and exclusive rights to develop, manufacture and commercialize JSKN016 in the Chinese Mainland, Hong Kong, Macau and Taiwan. Under the terms of the agreement, Alphamab is entitled to receive a non-refundable upfront payment of US$125 million and milestone payments based on the achievement of certain development and commercialization milestones, totaling up to US$2,093 million, as well as tiered royalties at high-single digit to low-double digit percentage rates according to aggregate annual net sales in the licensed territories. Accelerated by AI: The Foundry Advantage ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); JSKN016 was identified and prioritized through Foundry, Pathos’s proprietary AI-driven decision platform for oncology drug development. Foundry utilizes thousands of AI agents working in parallel, powered by the Pathos’ proprietary AI models, to analyze biological, clinical, and real-world data at scale; surfacing high-potential assets, designing clinical trials, and matching the right patients to the right therapies faster and more safely than traditional methods allow. Every major asset-level decision at Pathos flows through Foundry. JSKN016 becomes the fourth clinical-stage program advanced into the Pathos pipeline through the platform. "JSKN016 is a next-generation bispecific ADC with the potential to address significant unmet need across a range of solid tumors, and we are excited to advance it in partnership with Alphamab. This program was identified through Foundry, the same platform that continues to guide portfolio decisions across our clinical pipeline. This collaboration reflects our shared commitment to bringing differentiated therapies to patients." — Iker Huerga, CEO of Pathos AI "JSKN016 represents the best of our next-generation bispecific ADC platform, and we are excited to partner with Pathos. With Pathos's leading capabilities in AI-driven precision development, we are confident this collaboration will accelerate the global clinical advancement of JSKN016 and bring a potential breakthrough therapy to more patients with solid tumors. This partnership reflects our shared commitment to delivering differentiated innovation to patients worldwide." — Dr. Ting Xu, Chairman and CEO of Alphamab Oncology A Growing Mission to Transform Oncology The addition of JSKN016 expands Pathos’s clinical pipeline to four assets across multiple solid tumor indications. JSKN016, a TROP2/HER3 bispecific ADC, joins pocenbrodib, currently in development for metastatic castration-resistant prostate cancer (mCRPC) and relapsed/refractory multiple myeloma (RRMM); DO-2, for MET-altered non-small-cell lung cancer (NSCLC); and AZD4241, an ERα PROTAC for ER+/HER2- breast cancer being advanced under a collaboration with AstraZeneca. Every program in the Pathos pipeline has been identified, evaluated, or accelerated by the Foundry platform, reinforcing the company’s commitment to AI-native drug development. About JSKN016 JSKN016 is a TROP2/HER3 targeting bispecific ADC developed using the proprietary single-domain antibody and bispecific antibody platforms. It is conjugated via site-specific glycosylation to generate a homogeneous and stable ADC with a drug-to-antibody ratio (DAR) of 4. JSKN016 binds to TROP2 and/or HER3 on tumor cells, blocks the corresponding signaling pathways and releases topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects. JSKN016 has demonstrated superior efficacy and a favorable safety pro multiple solid tumors. Multiple clinical studies of JSKN016 as monotherapy and in combination therapies for lung cancer, breast cancer, and other indications have been initiated. The Phase III clinical study evaluating JSKN016 for the treatment of triple-negative breast cancer (TNBC) is currently ongoing. The Phase Ib clinical study in China and the Phase I clinical study in Australia of the subcutaneous formulation of JSKN016 are both ongoing. About Pathos AI Pathos AI is an AI and technology company advancing its own pipeline of cancer therapies. Its Foundry platform redesigns drug development from first principles: identifying clinical assets, making portfolio decisions with continuously updated probability-of-success calculations, and helping clinical teams guide clinical trials with AI-native monitoring. Pathos’s pipeline includes clinical-stage programs in mCRPC, multiple myeloma, MET-altered NSCLC, ER+/HER2- breast cancer, and TROP2/HER3-expressing solid tumors. About Alphamab Oncology Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms—including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies. Two products have received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment; and Anbenitamab (KN026, brand name: 恩尼妥®), the first domestically developed HER2 bispecific antibody approved for marketing in China, redefining the standard of treatment for second-line HER2-positive gastric cancer. Six bispecific ADC and dual-payload ADC candidates are currently in clinical development, and next-generation ADC pipelines are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, Glenmark, and Pathos AI, covering both product development and technology platforms. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide. Forward-Looking Statements This press release contains forward-looking statements. These statements involve risks and uncertainties that may cause actual results to differ materially. Pathos AI undertakes no obligation to update any forward-looking statement. Contacts For inquiries, please reach out to press@pathos.com

Phase 1License out/inADCDrug Approval

14 Jul 2026

·allsci.com

CSPC’s bispecific HER2 antibody and albumin-bound docetaxel secure BTD in China

CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to both docetaxel for injection (albumin-bound) (HB1801) and anbenitamab (KN026), a HER2-targeted bispecific antibody, for use in combination as first-line treatment of unresectable or metastatic HER2-positive breast cancer in adults. The designation accelerates regulatory review and provides more intensive NMPA guidance during development — and arrives five weeks after the Phase III Healer trial (KN026-003) reported that the combination met its primary endpoint of progression-free survival (PFS) against the current standard of care. Anbenitamab simultaneously binds two non-overlapping epitopes on the HER2 receptor, enabling dual-domain signal blockade through a single molecule. This mechanism is mechanistically distinct from the two-antibody approach of the trastuzumab-pertuzumab combination used in the standard THP regimen (trastuzumab plus pertuzumab plus docetaxel). Through antibody-induced receptor clustering, anbenitamab also enhances antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity while promoting HER2 receptor downregulation. HB1801 encapsulates docetaxel in human serum albumin, eliminating the polysorbate 80 and ethanol solvents required by conventional docetaxel formulations, removing the need for steroid premedication and permitting higher-concentration administration. The Healer trial (KN026-003) is a randomized, controlled, open-label, multicenter Phase III study designed to enroll approximately 880 patients with HER2-positive advanced breast cancer, assigned 1:1 to anbenitamab plus HB1801 or the THP regimen. The primary endpoint is PFS as assessed by a Blinded Independent Review Committee (BIRC). In June 2026, the Independent Data Monitoring Committee determined that the combination statistically significantly prolonged PFS and reduced the risk of disease progression or death compared with THP, with a trend toward an overall survival benefit. No specific hazard ratio, median PFS figures, or p-values have been disclosed; detailed data are expected at an upcoming international academic conference. The neoadjuvant Phase III trial (Neo-Healer, KN026-004) has provided the most granular publicly available efficacy data for this combination. Presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology Annual Meeting, the trial enrolled 521 patients with early or locally advanced HER2-positive breast cancer and randomized them 1:1 to anbenitamab plus HB1801 ± carboplatin or THP ± carboplatin for six cycles. The BIRC-assessed total pathological complete response (tpCR) rate was 62.4% (95% CI: 56.2–68.2) in the experimental arm versus 51.2% (95% CI: 44.9–57.4) in the control arm (one-sided p \= 0.0036). The Breakthrough Therapy Designation for the first-line advanced setting directly supports the companies’ stated plan to submit a New Drug Application (NDA) to the NMPA for this indication in the near future. Under China’s Breakthrough Therapy pathway, designated products receive priority scheduling, more frequent interactions with the NMPA’s Center for Drug Evaluation, and eligibility for rolling review. Anbenitamab had previously received NMPA Breakthrough Therapy Designation for HER2-positive advanced gastric cancer following failure of first-line treatment, and that program culminated in marketing authorization granted in May 2026. CSPC and its co-development partner, China-based Alphamab Oncology (HKEX: 09966), have positioned the HB1801 plus anbenitamab combination across the full HER2-positive breast cancer disease continuum. Phase III trials now cover neoadjuvant (Neo-Healer, primary endpoint met), adjuvant (ongoing), and first-line advanced (Healer, primary endpoint met) settings, with the Breakthrough Therapy Designation applying to the advanced first-line indication. The NDA submission for the neoadjuvant breast cancer indication is also described as forthcoming. Anbenitamab holds only an FDA Orphan Drug Designation for HER2-positive gastric cancer and has not entered US registration-enabling trials for breast cancer. The next material milestone is the public presentation of full Healer (KN026-003) efficacy and safety data, including the PFS hazard ratio, median PFS, and subgroup analyses, at an international academic conference. That dataset will determine whether the magnitude of PFS benefit over THP supports the regulatory and commercial case for the combination in first-line advanced HER2-positive breast cancer, and will inform the scope and timing of the planned NDA submission to the NMPA. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 3Clinical ResultBreakthrough TherapyNDAASCO

29 May 2026

·allsci.com

China approves CSPC’s HER2 BsAb Ennituo for gastric cancer post-Herceptin

China’s National Medical Products Administration has granted marketing authorization to Ennituo (anbenitamab; SYS6092; KN026 ), a recombinant humanised bispecific antibody co-developed by Shanghai JMT-BIO Technology — a subsidiary of CSPC Pharmaceutical Group and Jiangsu Alphamab Biopharmaceuticals, for the treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have previously received trastuzumab-containing therapy. The approval marks anbenitamab’s first cleared indication approval globally, and positions CSPC in a competitive second-line gastric cancer space increasingly defined by HER2-directed precision strategies. Ennituo is approved for use in combination with chemotherapy in this trastuzumab-pretreated population. Anbenitamab is an IgG1-type bispecific antibody that simultaneously engages two distinct, non-overlapping epitopes on HER2, a design intended to achieve more complete receptor blockade and enhanced internalization compared with conventional monospecific anti-HER2 agents. The molecule was originally developed by Alphamab Oncology using its proprietary CRIB heterodimer bispecific platform, with CSPC’s JMT-BIO subsidiary acquiring exclusive development and commercialisation rights for mainland China through a licensing agreement in August 2021. The approval rests primarily on data from KC-WISE, a pivotal Phase II/III trial enrolling patients with HER2-positive gastric or GEJ adenocarcinoma who had failed at least one prior line of therapy. Against standard chemotherapy alone, anbenitamab plus chemotherapy produced a progression-free survival of 7.1 months versus 2.7 months — a hazard ratio of 0.25, corresponding to a 75% reduction in the risk of disease progression or death. Overall survival reached 19.6 months in the combination arm compared with 11.5 months in the control arm (HR 0.25), a 71% reduction in mortality risk. Improvements in objective response rate and duration of response were also reported, with a safety profile described as favourable. The magnitude of the survival benefit observed in KC-WISE is notable in a disease setting where second-line options have historically offered modest gains. Anbenitamab’s dual-epitope engagement of HER2 is designed to prevent receptor re-expression and signalling through mechanisms that single-domain antibodies may not fully suppress, providing a mechanistic rationale for activity in patients who have already progressed on trastuzumab-based regimens. The most direct comparator in this space is fam-trastuzumab deruxtecan (Enhertu, T-DXd), the HER2-directed antibody-drug conjugate developed by Daiichi Sankyo and AstraZeneca, which carries FDA approval for HER2-positive gastric and GEJ adenocarcinoma in the post-trastuzumab setting based on the DESTINY-Gastric programme. Ramucirumab plus paclitaxel, approved for second-line gastric cancer regardless of HER2 status, remains a standard backbone against which novel agents in this line are benchmarked. Anbenitamab’s bispecific mechanism distinguishes it from both, though head-to-head data against these agents are not available from the source material. CSPC has also indicated that anbenitamab is under evaluation in HER2-positive breast cancer. A Phase III neoadjuvant study combining anbenitamab with HB1801 — the company’s proprietary albumin-bound docetaxel formulation — met its primary endpoint of total pathological complete response rate in March 2026. Registrational first-line breast cancer data from a separate Phase III study are expected later this year, suggesting the gastric approval may serve as a regulatory foundation for a broader oncology programme. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Drug ApprovalLicense out/inPhase 3Clinical ResultADC

100 Deals associated with Anbenitamab

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HER2 positive Gastroesophageal Junction Adenocarcinoma	China	Shanghai JMT Biological Technology Co Ltd	27 May 2026
HER2-positive gastric cancer	China	Shanghai JMT Biological Technology Co Ltd	27 May 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Breast Cancer	NDA/BLA	China	Shanghai JMT Biological Technology Co Ltd	04 Aug 2026
HER2 Positive Breast Cancer	NDA/BLA	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	04 Aug 2026
HER2 positive Gastrooesophageal junction cancer	Phase 3	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	27 Oct 2022
Advanced breast cancer	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022
Extensive stage Small Cell Lung Cancer	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022
Liver Cancer	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022
Lymphoma	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022
Melanoma	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022
Nasopharyngeal Carcinoma	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022
Non-Small Cell Lung Cancer	Phase 2	China	Suzhou Alphamab Co., Ltd.	08 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06747338 (ASCO2026)	Phase 3	HER2 Positive Breast Cancer Neoadjuvant HER2-positive	521	Anbenitamab plus nab-docetaxel ± carboplatin	ivfiphjobg(czxlskklhb) = chbhxaqhtd pupjdagzpn (qqhbvevkfk, 56.2 - 68.2) View more	Positive	29 May 2026
				trastuzumab, pertuzumab, and docetaxel ± carboplatin	ivfiphjobg(czxlskklhb) = hdaimeaujk pupjdagzpn (qqhbvevkfk, 44.9 - 57.4) View more
NCT05427383 (KC-WISE, Pubmed) Manual	Phase 3	HER2-positive gastric cancer Second line HER2 Positive	188	Anbenitamab 30 mg/kg + chemotherapy	mllxbtanbc(cvfekgirdo) = gugkfdvgvm fysimbiloj (miidjkzvjh, 5.5 - 10.3) View more	Positive	20 Jan 2026
				Chemotherapy	mllxbtanbc(cvfekgirdo) = barnzsivii fysimbiloj (miidjkzvjh, 1.5 - 3.0) View more
NCT05427383 (KC-WISE, ESMO2025)	Phase 3	Second line HER2-positive	188	Anbenitamab+chemotherapy	iejewiolwz(ehpzfghgps) = gcybwojwjn lhuwktrpny (xwccmpeejl ) View more	Positive	17 Oct 2025
				Placebo+chemotherapy	iejewiolwz(ehpzfghgps) = hdsvwfvcxr lhuwktrpny (xwccmpeejl ) View more
NCT05427383 (KN026-001, Company_Website) Manual	Phase 2/3	HER2 positive Gastrooesophageal junction cancer \| HER2-positive gastric cancer Second line HER2 Positive	-	KN026 + chemotherapy	kxldvgpfes(rlevpmohon) = significantly improved lrbmzqmfvw (jqchzwzigu ) Met View more	Positive	01 May 2025
NCT05427383 (ESMO2024 \| NEWS) Manual	Phase 2	HER2 Positive Gastroesophageal Adenocarcinoma Second line HER2 Positive	37	KN026 + Paclitaxel	mrdbzcqqae(ksyjcygyhn) = efnsrttioj wllhgakhqt (xljhucxoho, 3.78 - 13.11) Met View more	Positive	16 Sep 2024
NCT04165993 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	HER2 Positive Breast Cancer First line HER-2 positive	57	KN026 30 mg/kg + docetaxel 75 mg/m2	xislupexwf(bjhfcxzqod) = qasicxtyan qghitnxshk (ezfoaaknnh, 20.27 - NE) View more	Positive	21 Oct 2023
				KN026 30 mg/kg + docetaxel 75 mg/m2 (with visceral metastasis)	mklwbjdmqa(ysamlrawun) = adecsbdcpl pdduanqmgx (itbfaweuvd )
NCT04881929 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2 Positive \| HR Positive	30	KN026 + docetaxel	jomfzkmavg(ohnrzgtthi) = ldzumpqctj qesovhlbfu (hoxbhmmwkc, 37.43 - 74.53) View more	Positive	21 Oct 2023
NCT04521179 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	HER2 Positive Solid Tumors Last line HER2 Positive	26	KN026 30 mg/kg+KN046 5 mg/kg (CRC )	xybgvfpjon(ermeseqwdp) = oamyrqsgkz mljoatvfsc (xqenmnzyeq, 3.2 - NE) View more	Positive	26 May 2023
				overall	xybgvfpjon(ermeseqwdp) = oogtufudjy mljoatvfsc (xqenmnzyeq, 2.9 - 15.3) View more
NCT04881929 \| NCT05427383 \| NCT04040699 (KN026, SABCS2023)	Phase 2	Metastatic human epidermal growth factor 2 positive carcinoma of breast First line	57	KN026 30 mg/kg + Docetaxel 75 mg/m2	acnrieoeet(ltyjzrelqc) = mtkmkbxibk qoenilwrjx (npkktbrjqg, 12.45 - NE) View more	Positive	01 Mar 2023
NCT04881929 (KN026, SABCS2023)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant	15	KN026 + Docetaxel	vtwwsjignb(vclmffrmwk) = wihgwvydql fjhfumedas (gvjqlqafex, 69.2% - 100) View more	Positive	01 Mar 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis